Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817615) titled 'A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Condition:
Neovascular Age-related Macular Degeneration (nAMD)
Diabetic Macular Edema (DME)
Retinal Vein Occlusion (RVO)
Intervention:
Drug: GenSci148 Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First...